These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36599066)

  • 1. Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.
    Gandy S; Ehrlich ME
    N Engl J Med; 2023 Jan; 388(1):80-81. PubMed ID: 36599066
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advances in anti-beta antibody treatment of Alzheimer's disease].
    Zhang JH; Liang P
    Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):633-5. PubMed ID: 18070457
    [No Abstract]   [Full Text] [Related]  

  • 3. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
    Walsh DM; Klyubin I; Fadeeva JV; Rowan MJ; Selkoe DJ
    Biochem Soc Trans; 2002 Aug; 30(4):552-7. PubMed ID: 12196135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
    Cehlar O; Skrabana R; Revajova V; Novak M
    Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice.
    Xiao S; Song LL; Li JT; Wang H; Yu N; Wang ZQ; Zhang Y; He JS; Hung T
    J Alzheimers Dis; 2020; 73(2):657-670. PubMed ID: 31839610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyoxometalates as inhibitors of the aggregation of amyloid β peptides associated with Alzheimer's disease.
    Geng J; Li M; Ren J; Wang E; Qu X
    Angew Chem Int Ed Engl; 2011 Apr; 50(18):4184-8. PubMed ID: 21433228
    [No Abstract]   [Full Text] [Related]  

  • 7. Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease.
    Defelice FG; Ferreira ST
    An Acad Bras Cienc; 2002 Jun; 74(2):265-84. PubMed ID: 12098753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-beta.
    Wang J; Hara H; Makifuchi T; Tabira T
    J Alzheimers Dis; 2008 Jun; 14(2):161-73. PubMed ID: 18560128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.
    Andreasen N; Simeoni M; Ostlund H; Lisjo PI; Fladby T; Loercher AE; Byrne GJ; Murray F; Scott-Stevens PT; Wallin A; Zhang YY; Bronge LH; Zetterberg H; Nordberg AK; Yeo AJ; Khan SA; Hilpert J; Mistry PC
    PLoS One; 2015; 10(3):e0098153. PubMed ID: 25789616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel antibody targeting sequence 31-35 in amyloid β protein attenuates Alzheimer's disease-related neuronal damage.
    Cheng L; Zhang J; Li XY; Yuan L; Pan YF; Chen XR; Gao TM; Qiao JT; Qi JS
    Hippocampus; 2017 Feb; 27(2):122-133. PubMed ID: 27784133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein.
    Shimada M; Abe S; Takahashi T; Shiozaki K; Okuda M; Mizukami H; Klinman DM; Ozawa K; Okuda K
    PLoS One; 2013; 8(3):e57606. PubMed ID: 23555563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
    van Dyck CH
    Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-sheet breakers for Alzheimer's disease therapy.
    Bieler S; Soto C
    Curr Drug Targets; 2004 Aug; 5(6):553-8. PubMed ID: 15270201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic Modeling of Soluble Aβ Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer's Disease.
    Ferl GZ; Fuji RN; Atwal JK; Sun T; Ramanujan S; Quartino AL
    Curr Alzheimer Res; 2020; 17(4):393-406. PubMed ID: 32116192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genentech's Alzheimer's antibody trial to study disease prevention.
    Garber K
    Nat Biotechnol; 2012 Aug; 30(8):731-2. PubMed ID: 22871696
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence that a synthetic amyloid-ß oligomer-binding peptide (ABP) targets amyloid-ß deposits in transgenic mouse brain and human Alzheimer's disease brain.
    Chakravarthy B; Ito S; Atkinson T; Gaudet C; Ménard M; Brown L; Whitfield J
    Biochem Biophys Res Commun; 2014 Mar; 445(3):656-60. PubMed ID: 24569075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease.
    Baker-Nigh A; Vahedi S; Davis EG; Weintraub S; Bigio EH; Klein WL; Geula C
    Brain; 2015 Jun; 138(Pt 6):1722-37. PubMed ID: 25732182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.